JERUSALEM (Reuters) – Teva Pharmaceutical Industries reported slightly higher third-quarter profit, helped by sales of its Austedo treatment for Huntington’s Disease, and said production in Israel was unaffected by the country’s war with Hamas in Gaza.
The world’s largest generic drugmaker said on Wednesday it earned 60 cents per diluted share excluding one-time items in the July-September quarter, up from 59 cents per share a year earlier.
Revenue rose 7% to $3.9 billion, with Austedo sales up 30% in North America to $339 million.
Analysts had forecast earnings of 61 cents a share ex-items for the Israel-based company on revenue of $3.72 billion, I/B/E/S data from Refinitiv Eikon showed.
For 2023, Teva raised its revenue forecast slightly to $15.1-$15.5 billion from $15.0-$15.4 billion, after 2022 revenue of $14.9 billion.
It maintained its forecast of adjusted EPS of $2.25-$2.55, versus $2.52 in 2022.
(Reporting by Steven Scheer; Editing by Sharon Singleton)
